Patient characteristic (n = 184)
| Characteristics . | Value, no. (%) or mean ± SD . |
|---|---|
| Sex ratio, males/females | 95 (51.6)/89 (48.4) |
| Age at diagnosis of acute leukemia, y | 7.9 (0.5-18) |
| BMI at diagnosis of acute leukemia, kg/m2 | 16.0 (12.4-24.9) |
| Age at evaluation of MS, y | 21.2 (18-41) |
| BMI at evaluation of MS, kg/m2 | 22.1 (15.9-39.1) |
| Type of leukemia, no. (%) | |
| ALL | 150 (81.5) |
| AML | 34 (18.5) |
| Therapy for leukemia, no. (%) | |
| Chemotherapy without irradiation | 97 (52.7) |
| Chemotherapy with CNS irradiation | 27 (14.7) |
| Involved fields | |
| Cranial irradiation, no. (%) of CNS irradiation | 22/27 (81.5) |
| Craniospinal irradiation, no. (%) of CNS irradiation | 5/27 (12.5) |
| Irradiation dose | |
| 18 Gy, no. (%) of CNS irradiation | 20/27 (74.1) |
| 24 Gy, no. (%) of CNS irradiation | 5/27 (18.5) |
| Unknown, no. (%) of CNS irradiation | 2/27 (7.4) |
| Stem cell transplantation | 60 (32.6) |
| Allogeneic stem cell transplantation, no. (%) of transplanted patients | 39/60 (65.0) |
| Autologous stem cell transplantation, no. (%) of transplanted patients | 21/60 (35.0) |
| Total body irradiation, no. (%) of transplantation recipients | 43/60 (71.7) |
| Steroid therapy (any time) | 162 (88.0) |
| Transplantation-related complications, no. (%) of allogeneic recipients | |
| Acute GVHD grade ≥ 2 or chronic extensive GVHD | 18/39 (46.2) |
| Post-transplantation steroid | 32/39 (82.1) |
| Endocrine late side effects | |
| Hypogonadism | 36 (19.6) |
| Hormonal substitutive therapy, no. (%) of patients with hypogonadism | 28/36 (77.8) |
| Growth delay | 11 (6.0) |
| GH therapy, no. (%) of patients with growth delay | 5/11 (45.5) |
| Hypothyroidism, no. (%) of transplantation or irradiated patients | 15 (19.1) |
| Substitutive therapy, no. (%) of patients with hypothyroidism | 15/15 (100) |
| Obesity (BMI ≥ 30 kg/m2) | 10 (5.7) |
| Overweight (BMI, 25-29.9 kg/m2) | 38 (20.6) |
| Medication at evaluation | |
| Insulin/lipid-lowering agent/antihypertensive, no. (%) of MS patients | 1/17 (5.9) |
| Characteristics . | Value, no. (%) or mean ± SD . |
|---|---|
| Sex ratio, males/females | 95 (51.6)/89 (48.4) |
| Age at diagnosis of acute leukemia, y | 7.9 (0.5-18) |
| BMI at diagnosis of acute leukemia, kg/m2 | 16.0 (12.4-24.9) |
| Age at evaluation of MS, y | 21.2 (18-41) |
| BMI at evaluation of MS, kg/m2 | 22.1 (15.9-39.1) |
| Type of leukemia, no. (%) | |
| ALL | 150 (81.5) |
| AML | 34 (18.5) |
| Therapy for leukemia, no. (%) | |
| Chemotherapy without irradiation | 97 (52.7) |
| Chemotherapy with CNS irradiation | 27 (14.7) |
| Involved fields | |
| Cranial irradiation, no. (%) of CNS irradiation | 22/27 (81.5) |
| Craniospinal irradiation, no. (%) of CNS irradiation | 5/27 (12.5) |
| Irradiation dose | |
| 18 Gy, no. (%) of CNS irradiation | 20/27 (74.1) |
| 24 Gy, no. (%) of CNS irradiation | 5/27 (18.5) |
| Unknown, no. (%) of CNS irradiation | 2/27 (7.4) |
| Stem cell transplantation | 60 (32.6) |
| Allogeneic stem cell transplantation, no. (%) of transplanted patients | 39/60 (65.0) |
| Autologous stem cell transplantation, no. (%) of transplanted patients | 21/60 (35.0) |
| Total body irradiation, no. (%) of transplantation recipients | 43/60 (71.7) |
| Steroid therapy (any time) | 162 (88.0) |
| Transplantation-related complications, no. (%) of allogeneic recipients | |
| Acute GVHD grade ≥ 2 or chronic extensive GVHD | 18/39 (46.2) |
| Post-transplantation steroid | 32/39 (82.1) |
| Endocrine late side effects | |
| Hypogonadism | 36 (19.6) |
| Hormonal substitutive therapy, no. (%) of patients with hypogonadism | 28/36 (77.8) |
| Growth delay | 11 (6.0) |
| GH therapy, no. (%) of patients with growth delay | 5/11 (45.5) |
| Hypothyroidism, no. (%) of transplantation or irradiated patients | 15 (19.1) |
| Substitutive therapy, no. (%) of patients with hypothyroidism | 15/15 (100) |
| Obesity (BMI ≥ 30 kg/m2) | 10 (5.7) |
| Overweight (BMI, 25-29.9 kg/m2) | 38 (20.6) |
| Medication at evaluation | |
| Insulin/lipid-lowering agent/antihypertensive, no. (%) of MS patients | 1/17 (5.9) |
BMI indicates body mass index; AML, acute myeloid leukemia; and GVHD, graft-versus-host disease.